Core & Trust
Conflicts of Interest Policy
Every relationship that could bias a page
Nobody on the editorial team holds a financial interest in a company covered here, accepts payment from a provider, or works for one. If that ever changes, the relationship is disclosed on every affected page and the person is removed from the affected coverage.
Nobody on the editorial team holds a financial interest in a company covered here, accepts payment from a provider, or works for one. If that ever changes, the relationship is disclosed on every affected page and the person is removed from the affected coverage.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Someone raises it | A reader, a provider or an editor flags the issue. |
| 2 | It is assessed against the ledger | We reopen the source and the capture date. |
| 3 | A decision is recorded | Correct, clarify, or explain why the original stands. |
| 4 | The change is published and dated | Old figures stay visible in the log. |
| Area | Commitment | How you can check it |
|---|---|---|
| Every figure | Carries a source and a capture date | Open the provenance stamp beside it |
| Every clinical claim | Traced to a primary source | Follow the citation, not our summary |
| Every score | Computed from published inputs | Read the raw inputs on the provider page |
| Every correction | Dated and permanent | Read the corrections log |
| Every reviewer credential | not verified | Verification in progress |
What this policy covers
- Scope, in the reader's terms, not ours.
How we apply it
- Concrete process, with the responsible role named.
How to hold us to it
- Escalation route and expected response time.
Suspended reviewer credit — declared conflict of interest
On 26 July 2026 we suspended this publication's medical reviewer credit. Both individuals we had recorded as reviewers are named on a competing seller's own published pages as its medical director and prescribers.
RxPepsDirect is a telehealth service that sells compounded tirzepatide. Its published comparison of compounded tirzepatide telehealth services — in which it ranks itself the cheapest option — carries the byline “Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC”, names Dr Snipes as its medical director under NPI 1821250077, and lists both as its prescribers.
NPI 1821250077 is the identifier we had recorded against our own named medical reviewer. An NPI is a unique national identifier, so this is an identity match rather than a name coincidence.
What that means
Our conflicts policy states that no clinician reviews a page about a company they work for, consult to, or hold an interest in. Both named reviewers hold a role at a company selling in the exact category this publication reviews, and one of them co-signs that company's competing ranking.
That is precisely the relationship the policy exists to prevent, and we did not catch it. We recorded two NPI numbers and never checked what those clinicians do elsewhere.
What we have done
- Suspended the reviewer credit sitewide. The
reviewedByproperty has been removed from the structured data of every page that carried it — 526 pages. - Published the finding as COR-006 with the source and the date.
- Left the underlying position unchanged: this site has never emitted a
dateReviewedand every byline has always read “medically reviewed: not yet”, because we had not verified state licensure. No page has ever published a medically-reviewed claim under either name.
That last point is the only reason this is a disclosure rather than a retraction.
What has not been established
We have not spoken to either clinician. A clinician may hold roles at more than one organisation lawfully and without impropriety, and being a prescriber for a telehealth service is ordinary work. What is not compatible with our policy is that person also carrying a reviewer credit here while doing so.
Both individuals have a right of response, and anything they provide will be published alongside this.
Why this is on the site rather than quietly fixed
A conflicts policy that has never caught anything is decoration. This one caught something that costs us the one credentialed byline we had, and publishing it is the only version of the policy that means anything.
Related on this site
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
- About GLP-1 Tirzepatide ReviewCore & Trust
- Editorial StandardsCore & Trust
- Provider Ranking MethodologyCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Provider Right to RespondCore & Trust
- AI Use PolicyCore & Trust
- Terms of UseCore & Trust
- Methodology and Dataset ChangelogData
Related coverage
- Compounded Tirzepatide Online: Legal, Safety and Cost Guide
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- The Hidden Cost of GLP-1 Membership Fees
- Medicare GLP-1 Bridge: $50 a Month, and What the Fine Print Says
- Microdose Tirzepatide: The Evidence Gap
- Why Multi-Dose Vials Create Tirzepatide Dosing Errors
- The Oral GLP-1 Landscape in 2026
- Retatrutide Phase 3 Results: What Changed in July 2026
GLP-1 Tirzepatide Review. “Conflicts of Interest Policy.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/conflicts-of-interest/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.